Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Allogene Therapeutics, Inc. (ALLO)

2.0800 -0.1400 (-6.31%)
At close: June 30 at 4:00:00 PM EDT
2.0500 -0.0300 (-1.44%)
Pre-Market: 4:21:53 AM EDT
Trade ALLO on Coinbase
Chart Range Bar
Loading chart for ALLO
  • Previous Close 2.2200
  • Open 2.2400
  • Bid 1.6100 x 100
  • Ask 2.6300 x 200
  • Day's Range 2.0500 - 2.2500
  • 52 Week Range 0.9800 - 4.4600
  • Volume 17,953,667
  • Avg. Volume 10,895,669
  • Market Cap (intraday) 717.921M
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7700
  • Earnings Date (est.) Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 8.48

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

allogene.com

150

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ALLO
51.82%
S&P 500 (^GSPC)
9.55%

1-Year Return

ALLO
84.07%
S&P 500 (^GSPC)
20.86%

3-Year Return

ALLO
58.15%
S&P 500 (^GSPC)
68.51%

5-Year Return

ALLO
92.02%
S&P 500 (^GSPC)
74.51%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -42.61M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-40M
-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

3.85
8.48 Average
2.0800 Current
14.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/16/2026
Analyst JP Morgan
Rating Action Upgrade
Rating Neutral
Price Action --
Price Target --

Statistics

View More

Valuation Measures

Annual
As of 6/30/2026
  • Market Cap

    716.20M

  • Enterprise Value

    521.94M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.57

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -25.97%

  • Return on Equity (ttm)

    -52.32%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -173.76M

  • Diluted EPS (ttm)

    -0.7700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    266.89M

  • Total Debt/Equity (mrq)

    29.06%

  • Levered Free Cash Flow (ttm)

    -69.94M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.0800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: